Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Revathi Ananthakrishnan

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Critical Reviews in Oncology/Hematology|November 29, 2011
Integration of cell biology, pharmacological modeling and statistical analysis: part I: cell biology and PK/PD in the Oncology paradigmRevathi Ananthakrishnan, Sandeep Menon
International Journal of Biological Sciences|June 26, 2007
The forces behind cell movementRevathi Ananthakrishnan, Allen Ehrlicher
Critical Reviews in Oncology/Hematology|April 30, 2013
Design of oncology clinical trials: a reviewRevathi Ananthakrishnan, Sandeep Menon
Contemporary Clinical Trials Communications|December 5, 2019
2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacyRevathi Ananthakrishnan, Stephanie Green, Daniel Li, et al.
Journal of Biopharmaceutical Statistics|December 4, 2025
TITE-STEIN: Time-to-event simple toxicity and efficacy interval design to accelerate phase I/II trialsHao Sun, Jieqi Tu, Revathi Ananthakrishnan, et al.
Contemporary Clinical Trials Communications|April 27, 2018
Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trialsRevathi Ananthakrishnan, Stephanie Green, Daniel Li, et al.
Journal of Biopharmaceutical Statistics|November 17, 2024
Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncologyHao Sun, Hsin-Yu Lin, Jieqi Tu, et al.
Contemporary Clinical Trials Communications|July 11, 2022
An overview of the BOIN design and its current extensions for novel early-phase oncology trialsRevathi Ananthakrishnan, Ruitao Lin, Chunsheng He, et al.
Biophysical Journal|December 6, 2005
Weak force stalls protrusion at the leading edge of the lamellipodiumSophie Bohnet, Revathi Ananthakrishnan, Alex Mogilner, et al.
Contemporary Clinical Trials Communications|May 10, 2018
Systematic comparison of the statistical operating characteristics of various Phase I oncology designsRevathi Ananthakrishnan, Stephanie Green, Mark Chang, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Critical Reviews in Oncology/Hematology|November 29, 2011
Integration of cell biology, pharmacological modeling and statistical analysis: part I: cell biology and PK/PD in the Oncology paradigmRevathi Ananthakrishnan, Sandeep Menon
International Journal of Biological Sciences|June 26, 2007
The forces behind cell movementRevathi Ananthakrishnan, Allen Ehrlicher
Critical Reviews in Oncology/Hematology|April 30, 2013
Design of oncology clinical trials: a reviewRevathi Ananthakrishnan, Sandeep Menon
Contemporary Clinical Trials Communications|December 5, 2019
2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacyRevathi Ananthakrishnan, Stephanie Green, Daniel Li, et al.
Journal of Biopharmaceutical Statistics|December 4, 2025
TITE-STEIN: Time-to-event simple toxicity and efficacy interval design to accelerate phase I/II trialsHao Sun, Jieqi Tu, Revathi Ananthakrishnan, et al.
Contemporary Clinical Trials Communications|April 27, 2018
Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trialsRevathi Ananthakrishnan, Stephanie Green, Daniel Li, et al.
Journal of Biopharmaceutical Statistics|November 17, 2024
Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncologyHao Sun, Hsin-Yu Lin, Jieqi Tu, et al.
Contemporary Clinical Trials Communications|July 11, 2022
An overview of the BOIN design and its current extensions for novel early-phase oncology trialsRevathi Ananthakrishnan, Ruitao Lin, Chunsheng He, et al.
Biophysical Journal|December 6, 2005
Weak force stalls protrusion at the leading edge of the lamellipodiumSophie Bohnet, Revathi Ananthakrishnan, Alex Mogilner, et al.
Contemporary Clinical Trials Communications|May 10, 2018
Systematic comparison of the statistical operating characteristics of various Phase I oncology designsRevathi Ananthakrishnan, Stephanie Green, Mark Chang, et al.
Pageof 3